🇺🇸 FDA
Patent

US 8754081

Compositions and methods for inhibition of hepatocyte growth factor receptor c-Met signaling

granted A61PA61P35/00

Quick answer

US patent 8754081 (Compositions and methods for inhibition of hepatocyte growth factor receptor c-Met signaling) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jun 12 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Jun 17 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 12 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61P, A61P35/00